Marinus Pharmaceuticals Stock News

Brokerages forecast that Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) will announce ($0.81) earnings per share (EPS) for the current fiscal quarter, according to Zacks. Five analysts have issued estimates for Marinus Pharmaceuticals’ earnings, with estimates ranging from ($0.85) to ($0.76). Marinus Pharmaceuticals reported earnings of ($0.55) per share in the same quarter last year, which suggests a […]

JMP Securities restated their buy rating on shares of Marinus Pharmaceuticals (NASDAQ:MRNS) in a research note published on Tuesday morning, TipRanks reports. They currently have a $23.00 price target on the biopharmaceutical companys stock. MRNS has been the topic of several other research reports. Zacks Investment Research raised Marinus Pharmaceuticals from a hold rating to []

Shares of Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) have received a consensus recommendation of Buy from the eight brokerages that are presently covering the company, Marketbeat.com reports. Eight analysts have rated the stock with a buy recommendation. The average 1 year price objective among brokerages that have covered the stock in the last year is $30.83. Several []

Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Investment analysts at Truist Securiti lowered their FY2021 earnings estimates for Marinus Pharmaceuticals in a research note issued on Monday, December 6th. Truist Securiti analyst J. Lee now anticipates that the biopharmaceutical company will post earnings per share of ($2.68) for the year, down from their prior estimate of ($2.67). [] The post FY2021 Earnings Estimate for Marinus Pharmaceuticals, Inc. Issued By Truist Securiti (NASDAQ:MRNS) appeared first on ETF Daily News .

Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Truist Securiti lowered their FY2021 EPS estimates for Marinus Pharmaceuticals in a note issued to investors on Monday, December 6th. Truist Securiti analyst J. Lee now anticipates that the biopharmaceutical company will post earnings per share of ($2.68) for the year, down from their prior forecast of ($2.67). Truist Securiti []

Marinus Pharmaceuticals Announces New Clinical and Research Data to be Presented at American Epilepsy Society Meeting

California State Teachers Retirement System increased its holdings in Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) by 15.8% during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 50,899 shares of the biopharmaceutical company’s stock after purchasing an additional 6,962 shares during the period. […]

Marinus Pharmaceuticals, Inc. (MRNS) CEO Scott Braunstein on Q3 2021 Results - Earnings Call Transcript

Marinus Pharmaceuticals (MRNS) delivered earnings and revenue surprises of 30.26% and 335.95%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the

Marinus Pharmaceuticals (NASDAQ:MRNS) reported its Q3 earnings results on Tuesday, November 9, 2021 at 08:00 AM. Here's what investors need to know about the announcement.

RADNOR, Pa.--(BUSINESS WIRE)---- $MRNS #MarinusPharma--Marinus Pharmaceuticals to Provide Business Update and Announce Third Quarter 2021 Financial Results on November 9, 2021

RADNOR, Pa.--(BUSINESS WIRE)---- $MRNS #MarinusPharma--MARINUS PHARMACEUTICALS ANNOUNCES INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)

RADNOR, Pa.--(BUSINESS WIRE)---- $MRNS #MarinusPharma--Marinus Pharmaceuticals Announces Virtual R&D Event on October 5, 2021

RADNOR, Pa.--(BUSINESS WIRE)---- $MRNS #MarinusPharma--Marinus Pharmaceuticals Announces FDA Acceptance for Filing and Priority Review of New Drug Application for Ganaxolone in CDKL5 Deficiency Disord

RADNOR, Pa.--(BUSINESS WIRE)---- $MRNS #MarinusPharma--European Medicines Agency Grants Marinus Pharmaceuticals Accelerated Assessment of Ganaxolone for Treatment of CDKL5 Deficiency Disorder.